Literature DB >> 20008145

Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice.

Martin Floer1, Martin Götte, Martin K Wild, Jan Heidemann, Ezeddin Salem Gassar, Wolfram Domschke, Ludwig Kiesel, Andreas Luegering, Torsten Kucharzik.   

Abstract

Syndecan-1 (Sdc1) plays a major role in wound healing and modulates inflammatory responses. Sdc1 expression is reduced in lesions of patients with ulcerative colitis. The aim of this study was to investigate the role of Sdc1 in murine dextran sodium sulfate (DSS)-induced colitis. DSS colitis was induced in Sdc1-deficient (knockout (KO)) and wild-type mice by oral administration of 3% DSS. KO mice exhibited a significantly increased lethality as compared with wild-type controls (61 versus 5%, P < 0.05). Impaired mucosal healing and prolonged recruitment of inflammatory cells in KO mice were accompanied by significant up-regulation of tumor necrosis factor-alpha, CC chemokine ligand 3/macrophage inflammatory protein-1alpha, and vascular cell adhesion molecule-1, as determined by histological correlation between 0 and 15 days after colitis induction, TaqMan low-density array analysis, and quantitative real-time PCR. Treatment from days 7 through 14 with enoxaparin, a functional analogue of the Sdc1 heparan sulfate chains, significantly reduced lethality of KO mice due to DSS-induced colitis, which was correlated with improved mucosal healing. In vitro, Sdc1-deficient polymorphonuclear cells displayed increased adhesion to endothelial cells and intercellular adhesion molecule-1, and enoxaparin reverted adhesion to wild-type levels. Small interfering RNA-mediated knockdown of Sdc1 expression resulted in reduced basic fibroblast growth factor-mediated mitogen-activated protein kinase signaling and reduced Caco-2 cell proliferation. We conclude that Sdc1 has a protective effect during experimental colitis. The modification of missing Sdc1 function by heparin analogues may emerge as a promising anti-inflammatory approach.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20008145      PMCID: PMC2797877          DOI: 10.2353/ajpath.2010.080639

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  47 in total

Review 1.  Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.

Authors:  W J Sandborn; S B Hanauer
Journal:  Inflamm Bowel Dis       Date:  1999-05       Impact factor: 5.325

2.  Absence of CCR6 inhibits CD4+ regulatory T-cell development and M-cell formation inside Peyer's patches.

Authors:  Andreas Lügering; Martin Floer; Sabine Westphal; Christian Maaser; Thomas W Spahn; M Alexander Schmidt; Wolfram Domschke; Ifor R Williams; Torsten Kucharzik
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

Review 3.  Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease.

Authors:  R Day; A Forbes
Journal:  Lancet       Date:  1999-07-03       Impact factor: 79.321

4.  Heparan sulfate depletion amplifies TNF-alpha-induced protein leakage in an in vitro model of protein-losing enteropathy.

Authors:  Lars Bode; Erik A Eklund; Simon Murch; Hudson H Freeze
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2004-12-16       Impact factor: 4.052

5.  A comparison of observational studies and controlled trials of heparin in ulcerative colitis.

Authors:  S Malhotra; A Kondal; N Shafiq; S Sidhu; D K Bhasin; P Pandhi
Journal:  Int J Clin Pharmacol Ther       Date:  2004-12       Impact factor: 1.366

6.  VE-cadherin antibody accelerates neutrophil recruitment in vivo.

Authors:  U Gotsch; E Borges; R Bosse; E Böggemeyer; M Simon; H Mossmann; D Vestweber
Journal:  J Cell Sci       Date:  1997-03       Impact factor: 5.285

7.  Heparin, sulfated heparinoids, and lipoteichoic acids bind to the 70-kDa peptidoglycan/lipopolysaccharide receptor protein on lymphocytes.

Authors:  R Dziarski; D Gupta
Journal:  J Biol Chem       Date:  1994-01-21       Impact factor: 5.157

8.  Effects of the anti-ICAM-1 monoclonal antibody on dextran sodium sulphate-induced colitis in rats.

Authors:  T Taniguchi; H Tsukada; H Nakamura; M Kodama; K Fukuda; T Saito; M Miyasaka; Y Seino
Journal:  J Gastroenterol Hepatol       Date:  1998-09       Impact factor: 4.029

9.  Paradoxical response to heparin in 10 patients with ulcerative colitis.

Authors:  P R Gaffney; C T Doyle; A Gaffney; J Hogan; D P Hayes; P Annis
Journal:  Am J Gastroenterol       Date:  1995-02       Impact factor: 10.864

10.  Treatment of corticosteroid-resistant ulcerative colitis with heparin--a report of 16 cases.

Authors:  R C Evans; V S Wong; A I Morris; J M Rhodes
Journal:  Aliment Pharmacol Ther       Date:  1997-12       Impact factor: 8.171

View more
  32 in total

1.  A Proteoglycan-Like Molecule Offers Insights Into Ground Substance Changes During Holothurian Intestinal Regeneration.

Authors:  Gabriel E Vázquez-Vélez; José F Rodríguez-Molina; Mónica C Quiñones-Frías; María Pagán; José E García-Arrarás
Journal:  J Histochem Cytochem       Date:  2016-04-28       Impact factor: 2.479

Review 2.  Molecular functions of syndecan-1 in disease.

Authors:  Yvonne Hui-Fang Teng; Rafael S Aquino; Pyong Woo Park
Journal:  Matrix Biol       Date:  2011-10-18       Impact factor: 11.583

Review 3.  Microbial metabolites and derivatives targeted at inflammation and bone diseases therapy: chemistry, biological activity and pharmacology.

Authors:  Hayamitsu Adachi; Koichi Nakae; Shuichi Sakamoto; Chisato Nosaka; Sonoko Atsumi; Masabumi Shibuya; Nobuaki Higashi; Motowo Nakajima; Tatsuro Irimura; Yoshio Nishimura
Journal:  J Antibiot (Tokyo)       Date:  2017-11-01       Impact factor: 2.649

4.  The role for decorin in delayed-type hypersensitivity.

Authors:  Daniela G Seidler; Negia A Mohamed; Carla Bocian; Anika Stadtmann; Sven Hermann; Klaus Schäfers; Michael Schäfers; Renato V Iozzo; Alexander Zarbock; Martin Götte
Journal:  J Immunol       Date:  2011-10-31       Impact factor: 5.422

5.  Soluble Syndecan-1 Levels Are Elevated in Patients with Inflammatory Bowel Disease.

Authors:  Doron Yablecovitch; Assaf Stein; Maytal Shabat-Simon; Timna Naftali; Gila Gabay; Ido Laish; Asaf Oren; Fred M Konikoff
Journal:  Dig Dis Sci       Date:  2015-02-22       Impact factor: 3.199

Review 6.  Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.

Authors:  Ralph D Sanderson; Michael Elkin; Alan C Rapraeger; Neta Ilan; Israel Vlodavsky
Journal:  FEBS J       Date:  2016-11-16       Impact factor: 5.542

Review 7.  Versatile role of heparanase in inflammation.

Authors:  Rachel Goldberg; Amichay Meirovitz; Nir Hirshoren; Raanan Bulvik; Adi Binder; Ariel M Rubinstein; Michael Elkin
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

8.  The endothelial glycocalyx in syndecan-1 deficient mice.

Authors:  Michele D Savery; John X Jiang; Pyong Woo Park; Edward R Damiano
Journal:  Microvasc Res       Date:  2013-02-19       Impact factor: 3.514

Review 9.  Heparanase in inflammation and inflammation-associated cancer.

Authors:  Amichay Meirovitz; Rachel Goldberg; Adi Binder; Ariel M Rubinstein; Esther Hermano; Michael Elkin
Journal:  FEBS J       Date:  2013-03-04       Impact factor: 5.542

Review 10.  Heparanase enzyme in chronic inflammatory bowel disease and colon cancer.

Authors:  Esther Hermano; Immanuel Lerner; Michael Elkin
Journal:  Cell Mol Life Sci       Date:  2012-02-14       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.